Initially, their discovery caused considerable excitement among diabetologists; however, shortly afterwards the use of SGLT-2 inhibitors appeared to be associated with favorable outcomes in kidney disease and HF as well, irrespective of DM. Here, SLC5A2 is linked to kidney disorder.